ArticleACS nano2017
Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific Immunomodulators.
Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Engineering polycaprolactone nanowires for pharmacologic efficacy.Expert opinion on drug delivery · 2025Article
- Nanomaterial assisted natural killer cell therapy.Frontiers in immunology · 2025Review
- Apical integrins as a switchable target to regulate the epithelial barrier.Journal of cell science · 2024Article
- NK cell-based tumor immunotherapy.Bioactive materials · 2024Review
- Precise surface functionalization of PLGA particles for human T cell modulation.Nature protocols · 2023Article
- Harnessing Biomaterials for Immunomodulatory-Driven Tissue Engineering.Regenerative engineering and translational medicine · 2023Review
- Bioinspired Polymeric High Aspect Ratio Particles with Asymmetric Janus Functionalities.Advanced nanobiomed research · 2021Article
- DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation.Nature nanotechnology · 2021Article
- Engineering the drug carrier biointerface to overcome biological barriers to drug delivery.Advanced drug delivery reviews · 2020Review
- Networks of High Aspect Ratio Particles to Direct Colloidal Assembly Dynamics and Cellular Interactions.Advanced functional materials · 2020Article
- TiOACS biomaterials science & engineering · 2020Article
- An Injectable Cytokine Trap for Local Treatment of Autoimmune Disease.Biomaterials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Injectable nanomaterials that interact with the host immune system without surgical intervention present spatially anchored complements to cell transplantation and could offer improved pharmacokinetics compared to systemic cytokine therapy. Here we demonstrate fabrication of high aspect ratio polycaprolactone nanowires coupled with cytokine-binding antibodies that assemble into porous matrices when injected into the subcutaneous space. These structures are fabricated using a nanotemplating technique that allows for tunability of particle dimensions and utilize a straightforward maleimide conjugation chemistry to allow site-specific coupling to proteins. Nanowires are well tolerated in vivo and incite minimal inflammatory infiltrate. Nanowires conjugated with antibodies were designed to capture and potentiate endogenous interleukin-2 (IL-2), an important leukocyte activating cytokine. Together these nanowire-antibody matrices were capable of localizing endogenous IL-2 in the skin and activated targeted specific natural killer and T cell subsets, demonstrating both tissue- and cell-specific immune activation. These self-assembling nanowire matrices show promise as scaffolds to present engineered, local receptor-ligand interactions for cytokine-mediated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.